Peptide Library

Research statistics

Goserelin research: publications and trials

What has been published on Goserelin: PubMed publications, the kind of evidence they report and registered clinical trials. These are counts of research, not a judgment of whether Goserelin works or is safe. For what it is and what the studies found, see the Goserelin profile.
Automated weekly refresh · data through November 1, 2026

At a glance

Publications, all years

1,957

Since 1978

Publications in 2026 so far

24

Through November 1, 2026

Human clinical research

73.7%

1,385 of 1,878 classified

Registered clinical trials

301

ClinicalTrials.gov

Randomized controlled trials

429

Publications reporting an RCT in people

Systematic reviews and meta-analyses

34

Preclinical studies

9.8%

118 animal · 50 in vitro · 16 computational

Records that only mention it

241

Not counted above

Status in the library: FDA-approved. 79 publications are not yet classified by study type.

What to keep in mind

  • Some completed trials have neither posted results nor a linked results publication.

Publications by year

Goserelin publications by year and evidence

1978, Preclinical (animal, in vitro, computational): 1 of 11979, Preclinical (animal, in vitro, computational): 1 of 11980, Preclinical (animal, in vitro, computational): 1 of 11981, Preclinical (animal, in vitro, computational): 2 of 21982, Human clinical research: 1 of 31982, Preclinical (animal, in vitro, computational): 1 of 31982, Reviews and meta-analyses: 1 of 31983, Human clinical research: 5 of 91983, Preclinical (animal, in vitro, computational): 3 of 91983, Other and not yet classified: 1 of 91984, Human clinical research: 4 of 121984, Preclinical (animal, in vitro, computational): 4 of 121984, Reviews and meta-analyses: 1 of 121984, Other and not yet classified: 3 of 121985, Human clinical research: 4 of 111985, Preclinical (animal, in vitro, computational): 4 of 111985, Reviews and meta-analyses: 1 of 111985, Other and not yet classified: 2 of 111986, Human clinical research: 11 of 181986, Preclinical (animal, in vitro, computational): 2 of 181986, Other and not yet classified: 5 of 181987, Human clinical research: 15 of 311987, Preclinical (animal, in vitro, computational): 5 of 311987, Reviews and meta-analyses: 1 of 311987, Other and not yet classified: 10 of 311988, Human clinical research: 32 of 431988, Preclinical (animal, in vitro, computational): 4 of 431988, Reviews and meta-analyses: 1 of 431988, Other and not yet classified: 6 of 431989, Human clinical research: 32 of 611989, Preclinical (animal, in vitro, computational): 10 of 611989, Reviews and meta-analyses: 5 of 611989, Other and not yet classified: 14 of 611990, Human clinical research: 50 of 661990, Preclinical (animal, in vitro, computational): 4 of 661990, Reviews and meta-analyses: 5 of 661990, Other and not yet classified: 7 of 661991, Human clinical research: 40 of 601991, Preclinical (animal, in vitro, computational): 4 of 601991, Reviews and meta-analyses: 4 of 601991, Other and not yet classified: 12 of 601992, Human clinical research: 37 of 551992, Preclinical (animal, in vitro, computational): 7 of 551992, Reviews and meta-analyses: 6 of 551992, Other and not yet classified: 5 of 551993, Human clinical research: 52 of 611993, Preclinical (animal, in vitro, computational): 1 of 611993, Reviews and meta-analyses: 4 of 611993, Other and not yet classified: 4 of 611994, Human clinical research: 51 of 741994, Preclinical (animal, in vitro, computational): 5 of 741994, Reviews and meta-analyses: 7 of 741994, Other and not yet classified: 11 of 741995, Human clinical research: 40 of 491995, Preclinical (animal, in vitro, computational): 4 of 491995, Reviews and meta-analyses: 2 of 491995, Other and not yet classified: 3 of 491996, Human clinical research: 53 of 701996, Preclinical (animal, in vitro, computational): 4 of 701996, Reviews and meta-analyses: 6 of 701996, Other and not yet classified: 7 of 701997, Human clinical research: 39 of 481997, Preclinical (animal, in vitro, computational): 3 of 481997, Reviews and meta-analyses: 2 of 481997, Other and not yet classified: 4 of 481998, Human clinical research: 34 of 521998, Preclinical (animal, in vitro, computational): 4 of 521998, Reviews and meta-analyses: 11 of 521998, Other and not yet classified: 3 of 521999, Human clinical research: 41 of 521999, Preclinical (animal, in vitro, computational): 2 of 521999, Reviews and meta-analyses: 3 of 521999, Other and not yet classified: 6 of 522000, Human clinical research: 41 of 632000, Preclinical (animal, in vitro, computational): 4 of 632000, Reviews and meta-analyses: 13 of 632000, Other and not yet classified: 5 of 632001, Human clinical research: 44 of 582001, Preclinical (animal, in vitro, computational): 4 of 582001, Reviews and meta-analyses: 7 of 582001, Other and not yet classified: 3 of 582002, Human clinical research: 46 of 692002, Preclinical (animal, in vitro, computational): 6 of 692002, Reviews and meta-analyses: 12 of 692002, Other and not yet classified: 5 of 692003, Human clinical research: 35 of 582003, Preclinical (animal, in vitro, computational): 3 of 582003, Reviews and meta-analyses: 13 of 582003, Other and not yet classified: 7 of 582004, Human clinical research: 33 of 402004, Preclinical (animal, in vitro, computational): 1 of 402004, Reviews and meta-analyses: 4 of 402004, Other and not yet classified: 2 of 402005, Human clinical research: 44 of 612005, Preclinical (animal, in vitro, computational): 3 of 612005, Reviews and meta-analyses: 10 of 612005, Other and not yet classified: 4 of 612006, Human clinical research: 42 of 542006, Preclinical (animal, in vitro, computational): 3 of 542006, Reviews and meta-analyses: 7 of 542006, Other and not yet classified: 2 of 542007, Human clinical research: 39 of 552007, Preclinical (animal, in vitro, computational): 5 of 552007, Reviews and meta-analyses: 9 of 552007, Other and not yet classified: 2 of 552008, Human clinical research: 40 of 522008, Preclinical (animal, in vitro, computational): 5 of 522008, Reviews and meta-analyses: 3 of 522008, Other and not yet classified: 4 of 522009, Human clinical research: 44 of 602009, Preclinical (animal, in vitro, computational): 2 of 602009, Reviews and meta-analyses: 5 of 602009, Other and not yet classified: 9 of 602010, Human clinical research: 36 of 492010, Preclinical (animal, in vitro, computational): 7 of 492010, Reviews and meta-analyses: 1 of 492010, Other and not yet classified: 5 of 492011, Human clinical research: 36 of 472011, Preclinical (animal, in vitro, computational): 2 of 472011, Reviews and meta-analyses: 4 of 472011, Other and not yet classified: 5 of 472012, Human clinical research: 42 of 512012, Preclinical (animal, in vitro, computational): 4 of 512012, Reviews and meta-analyses: 2 of 512012, Other and not yet classified: 3 of 512013, Human clinical research: 41 of 602013, Preclinical (animal, in vitro, computational): 6 of 602013, Reviews and meta-analyses: 3 of 602013, Other and not yet classified: 10 of 602014, Human clinical research: 26 of 422014, Preclinical (animal, in vitro, computational): 5 of 422014, Reviews and meta-analyses: 7 of 422014, Other and not yet classified: 4 of 422015, Human clinical research: 31 of 522015, Preclinical (animal, in vitro, computational): 8 of 522015, Reviews and meta-analyses: 5 of 522015, Other and not yet classified: 8 of 522016, Human clinical research: 21 of 302016, Preclinical (animal, in vitro, computational): 5 of 302016, Reviews and meta-analyses: 3 of 302016, Other and not yet classified: 1 of 302017, Human clinical research: 18 of 242017, Preclinical (animal, in vitro, computational): 4 of 242017, Reviews and meta-analyses: 1 of 242017, Other and not yet classified: 1 of 242018, Human clinical research: 22 of 292018, Reviews and meta-analyses: 6 of 292018, Other and not yet classified: 1 of 292019, Human clinical research: 24 of 302019, Preclinical (animal, in vitro, computational): 4 of 302019, Reviews and meta-analyses: 2 of 302020, Human clinical research: 16 of 242020, Preclinical (animal, in vitro, computational): 4 of 242020, Reviews and meta-analyses: 3 of 242020, Other and not yet classified: 1 of 242021, Human clinical research: 21 of 272021, Preclinical (animal, in vitro, computational): 3 of 272021, Reviews and meta-analyses: 3 of 272022, Human clinical research: 13 of 242022, Preclinical (animal, in vitro, computational): 6 of 242022, Reviews and meta-analyses: 5 of 242023, Human clinical research: 17 of 222023, Preclinical (animal, in vitro, computational): 4 of 222023, Reviews and meta-analyses: 1 of 222024, Human clinical research: 25 of 332024, Preclinical (animal, in vitro, computational): 4 of 332024, Reviews and meta-analyses: 2 of 332024, Other and not yet classified: 2 of 332025, Human clinical research: 29 of 392025, Preclinical (animal, in vitro, computational): 6 of 392025, Reviews and meta-analyses: 3 of 392025, Other and not yet classified: 1 of 392026 (to date), Human clinical research: 18 of 242026 (to date), Reviews and meta-analyses: 5 of 242026 (to date), Other and not yet classified: 1 of 24Human clinical researchPreclinical (animal, in vitro, computational)Reviews and meta-analysesOther and not yet classified020406080197819881998200820182026*
Counted PubMed publications by year of first publication. * 2026 runs to November 1, 2026. A larger bar is more publications, not stronger evidence.
Show the data
YearHuman clinical researchPreclinical (animal, in vitro, computational)Reviews and meta-analysesOther and not yet classifiedTotal
197801001
197901001
198001001
198102002
198211103
198353019
1984441312
1985441211
19861120518
198715511031
19883241643
1989321051461
19905045766
199140441260
19923776555
19935214461
199451571174
19954042349
19965346770
19973932448
199834411352
19994123652
200041413563
20014447358
200246612569
200335313758
20043314240
200544310461
20064237254
20073959255
20084053452
20094425960
20103671549
20113624547
20124242351
201341631060
20142657442
20153185852
20162153130
20171841124
20182206129
20192442030
20201643124
20212133027
20221365024
20231741022
20242542233
20252963139
2026 (to date)1805124

Study types

Randomized controlled trial429
Observational human study346
Other clinical trial332
Case report278
Review165
Animal study118
Editorial, letter or other107
Not yet classified79
In vitro study50
Meta-analysis25
Computational study16
Systematic review9
Guideline or consensus2
Correction or retraction notice1

Research areas

From MeSH major topics. A paper can be in several areas.

Oncology1,514
Reproductive and sexual health1,349
Dermatology382
Endocrinology288
Musculoskeletal115
Neurological and mental health98
Metabolic health53
Gastrointestinal44
Cardiovascular43
Immune system31
Tissue repair29
Cognitive health15

Registered clinical trials

38 of 127 trials completed at least a year before the cutoff have neither posted results nor a linked results publication. A registration is not a result.

Completed: 142 · Unknown status: 48 · Terminated: 34 · Active, not recruiting: 29 · Recruiting: 26 · Withdrawn: 12 · Not yet recruiting: 9 · Suspended: 1
Early phase 1: 1 · Phase not applicable: 27 · Phase 1: 23 · Phase 1 / Phase 2: 8 · Phase 2: 125 · Phase 2 / Phase 3: 7 · Phase 3: 91 · Phase 4: 19

TrialStatusPhaseStartedResults
A Trial to Evaluate Ovarian Suppression Following Subcutaneous ZOLADEX 10.8 mg in Premenopausal Women With Early-stage and Advanced HR+ Breast CancerNCT07310420 · 176 enrolledRecruitingPhase 12026-10—
ADT De-escalation in Selected High-Risk Prostate Cancer Patients (ADaPPt Trial) a GROUQ Led PCS Study (PCS XIV)NCT07777263 · 600 enrolledNot yet recruitingPhase 32026-10—
QL1706 Plus Neoadjuvant Endocrine Therapy in HR-Positive/HER2-Negative Breast Cancer With a Poor Response to Neoadjuvant ChemotherapyNCT07782840 · 40 enrolledNot yet recruitingPhase 22026-10—
Neoadjuvant Endocrine Therapy Combined With Chemotherapy in ER-positive, HER2-negative Stage I-III Breast CancerNCT07801898 · 36 enrolledNot yet recruitingPhase 22026-09—
BRE-06: Study to Increase Tolerance to Aromatase Inhibitors for Patients With Early-Stage Hormone Receptor Positive Breast Cancer Who Developed Hypoactive Sexual Desire DisorderNCT07596212 · 100 enrolledNot yet recruitingPhase 1, Phase 22026-09—
Evaluating Hormone Therapy to Achieve Optimal Doses in Metastatic Prostate CancerNCT07751133 · 1,500 enrolledRecruitingPhase 32026-08—
Evaluation of Alternative Site Goserelin Acetate Injection for Ovarian Function Suppression (OFS) in Local and Locally Advanced Premenopausal Hormone Receptor Positive Breast Cancer PatientsNCT07460752 · 98 enrolledRecruitingPhase 22026-05—
A Study of Imlunestrant (LY3484356) in Premenopausal Women With Estrogen Receptor-Positive (ER+) Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Early Breast CancerNCT07287098 · 600 enrolledRecruitingPhase 22026-05—
Clinical Study on the Preservation of Ovarian Function Following Hematopoietic Stem Cell Transplantation in Patients With Malignant Hematologic Diseases Using GoserelinNCT07552480 · 64 enrolledNot yet recruitingPhase not applicable2026-05—
Clinical Study on the Preservation of Ovarian Function Following Autologous Hematopoietic Stem Cell Transplantation Using GoserelinNCT07552493 · 64 enrolledNot yet recruitingPhase not applicable2026-05—
Clinical Study on the Preservation of Ovarian Function in Patients With Aplastic Anemia Following Allogeneic Hematopoietic Stem Cell Transplantation Using GoserelinNCT07552506 · 132 enrolledNot yet recruitingPhase not applicable2026-05—
Leuprolide and Goserelin for Ovarian Function Suppression in Pre- or Peri-menopausal Women With Breast Cancer, OFS TrialNCT07158021 · 75 enrolledRecruitingPhase 22026-01—
Maintenance Therapy in HER2-Positive Unresectable Locally Recurrent or Metastatic Breast Cancer: A Phase II StudyNCT07179939 · 288 enrolledNot yet recruitingPhase 22025-09—
The COSMYC Trial (COmbined Suppression of MYC)NCT06922318 · 50 enrolledRecruitingPhase 22025-08—
A Study to Assess the Bioequivalence of Follitropin Alfa Solution in Pen and Follitropin Alfa Powder in Vial in Healthy Downregulated Male ParticipantsNCT07097259 · 55 enrolledCompletedPhase 12025-07—
Impact of Omitting Chemo Based on Patient's Selection for ER-Positive, HER2-Negative Breast Cancer With Ribociclib and Endocrine TherapyNCT06953882 · 140 enrolledRecruitingPhase 22025-07—
Pembrolizumab With Androgen Deprivation Therapy and Radiotherapy for the Treatment of Patients With High Risk Localized Prostate CancerNCT06528210WithdrawnPhase 22025-04—
Assessing the Efficacy and Safety of Anti-HER2 Therapy in Nigerian Women With HER2+ Breast Cancer Before and After SurgeryNCT06348134 · 74 enrolledRecruitingPhase 22025-03—
Pilot Study of Neoadjuvant Chemotherapy Combined With Immunotherapy and Multimodal Thermal Therapy for HER2-negative Breast CancerNCT06636591 · 14 enrolledCompletedPhase not applicable2024-12—
Effect of a GnRH Analog on Hepatic SteatosisNCT06523530 · 62 enrolledActive, not recruitingPhase 42024-11—
Artificial Intelligence to Personalize Prostate Cancer Treatment (the HypoElect Trial)NCT06582446 · 30 enrolledRecruitingPhase 22024-09—
Neoadjuvant Chemotherapy With or Without GnRH Agonist for Premenopausal Triple-negative Early Breast Cancer PatientsNCT06225284 · 124 enrolledRecruitingPhase 22024-08—
Adaptions and Resiliency to Multi-Stressor OpeRationsNCT06455969 · 120 enrolledRecruitingPhase 42024-07—
To Assess The Patient Preference for Goserelin Microsphere Versus Goserelin Implant in Patients With Prostate CancerNCT06385847 · 60 enrolledUnknown statusPhase 22024-05—
Neoadjuvant Therapy of Darolutamide Plus ADT for High Risk Prostate CancerNCT06575257 · 80 enrolledRecruitingPhase 22024-05—
Genomic Biomarker-guided Neoadjuvant Therapy for Prostate Cancer (SEGNO)NCT06387056 · 40 enrolledRecruitingPhase 22024-04—
Phase IIIb Study of Ribociclib + ET in Early Breast CancerNCT05827081 · 1,464 enrolledActive, not recruitingPhase 32024-02—
First-Line Ribociclib Plus Endocrine Therapy Versus Chemotherapy With or Without Subsequent Endocrine Therapy in Patients With Rapidly Progressive HR-Positive/HER2-Negative Advanced Breast CancerNCT06375707 · 74 enrolledCompletedPhase 22024-01—
Treatment of High-Risk Prostate Cancer Guided by Novel Diagnostic Radio- and Molecular TracersNCT06282588 · 493 enrolledRecruitingPhase 2, Phase 32023-12—
[177Lu]Lu-NeoB in Combination With Ribociclib and Fulvestrant in Participants With ER+, HER2- and GRPR+ Advanced Breast CancerNCT05870579 · 28 enrolledActive, not recruitingPhase 12023-11—
Difluoromethylornithine and High Dose Testosterone With Enzalutamide in Metastatic Castration-Resistant Prostate CancerNCT06059118 · 50 enrolledRecruitingPhase 22023-10—
Contributions to Hypertension With Androgen Deprivation TherapyNCT05700903 · 10 enrolledTerminatedPhase 42023-09Posted
Precision Treatment of Recurrent/Metastatic Salivary Gland Carcinoma Guided by Molecular TypingNCT06145308 · 39 enrolledRecruitingPhase 22023-08—
Neo-DAB: Darolutamide and Abemaciclib in Prostate CancerNCT05617885 · 9 enrolledTerminatedPhase 12023-08Posted
To Prevent Type I-II Myoma After TCRM Recurrence by Gonadotropin-releasing Hormone (GnRH )Analogues or MifepristoneNCT05898321 · 294 enrolledUnknown statusPhase not applicable2023-06—
Pharmacokinetics Pharmacodynamics and Safety of LY01022 in Patients With Prostate Cancer Compared With Zoladex® 10.8mgNCT05856630 · 24 enrolledUnknown statusPhase 12023-05—
Short Versus Long-term Androgen Deprivation Therapy With Salvage Radiotherapy in Prostate Cancer. URONCOR 0624NCT05781217 · 534 enrolledRecruitingPhase 32023-03—
(Z)-Endoxifen for the Treatment of Premenopausal Women With ER+/HER2- Breast CancerNCT05607004 · 87 enrolledActive, not recruitingPhase 22023-02—
Real World Evidence Study on Metastatic Prostate Cancer in the Pirkanmaa Hospital District in FinlandNCT05701007 · 1,083 enrolledCompletedPhase not applicable2023-02Posted
Study of Neoadjuvant PARP Inhibition Followed by Radical Prostatectomy in Patients With Unfavorable Intermediate-Risk or High-Risk Prostate Cancer With Select HRR Gene AlterationsNCT05498272 · 32 enrolledActive, not recruitingPhase 22023-02—
Immunotherapy, Hormone Therapy, and AKT Inhibitor for Premenopausal ER Positive MBCNCT05720260 · 42 enrolledRecruitingPhase 22023-01—
SNF Platform Study of HR+/ HER2-advanced Breast CancerNCT05594095 · 620 enrolledRecruitingPhase 22022-12—
Neoadjuvant Treatment of Locally-advanced Breast Cancer Patients With Ribociclib and LetrozoleNCT05163106 · 85 enrolledCompletedPhase 22022-12—
Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant TherapyNCT05582499 · 716 enrolledRecruitingPhase 22022-11—
Phase II Dutasteride in Combination With CAB vs CAB in SDCNCT05513365 · 26 enrolledRecruitingPhase 22022-09—
Roll-over Study to Allow Continued Access to RibociclibNCT05161195 · 134 enrolledActive, not recruitingPhase 42022-07—
Enhanced Systemic Combined With Local Treatment for Primary and Metastatic Lesions in Oligo-metastatic Prostate CancerNCT05212857 · 160 enrolledUnknown statusPhase 22022-04—
Pilot Decentralized Clinical Trial in Men and Pre and Post-menopausal Women With Breast Cancer and a Specific Mutation (PIK3CA) Treated With Alpelisib in Combination With FulvestrantNCT04862143 · 2 enrolledTerminatedPhase 22022-03Posted
This is a Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Clinical Study Evaluating the Efficacy and Safety of FCN-437c Versus Placebo in Combination With Letrozole or Anastrozole ± Goserelin in Women With HR+ and HER2- Advanced Breast Cancer.NCT05439499 · 434 enrolledUnknown statusPhase 32022-03—
RWE About QOL and Compliance of Patients With OFS in ChinaNCT05122377 · 562 enrolledCompletedPhase not applicable2022-03—

The 50 most recently started of 301 trials.

Human trials and evidence reviews

Meta-analyses, systematic reviews and trials in people, newest first.

  1. Meta-analysis of the effect of goserelin acetate implant on improving hormone levels in patients with endometriosis.

    Pakistan journal of pharmaceutical sciences · April 1, 2026 · Meta-analysis · cited 0 times · open access

    PMID 41761808 · DOI 10.36721/pjps.2026.39.4.reg.14460.1 · Reviews and meta-analyses

  2. Effect of Medical Therapies for Endometriosis on Bone Health: A Systematic Review and Meta-analysis.

    Obstetrics and gynecology · March 19, 2026 · Meta-analysis · cited 2 times

    PMID 41855532 · DOI 10.1097/aog.0000000000006241 · Reviews and meta-analyses

  3. Progestogens or progestogen-releasing intrauterine systems for uterine fibroids (other than preoperative medical therapy).

    The Cochrane database of systematic reviews · November 23, 2020 · Meta-analysis · cited 33 times · open access

    PMID 33226133 · DOI 10.1002/14651858.cd008994.pub3 · Reviews and meta-analyses

  4. Laparoscopic surgery for endometriosis.

    The Cochrane database of systematic reviews · October 23, 2020 · Meta-analysis · cited 126 times

    PMID 33095458 · DOI 10.1002/14651858.cd011031.pub3 · Reviews and meta-analyses

  5. Oral contraceptives for pain associated with endometriosis.

    The Cochrane database of systematic reviews · May 22, 2018 · Meta-analysis · cited 199 times · open access

    PMID 29786828 · DOI 10.1002/14651858.cd001019.pub3 · Reviews and meta-analyses

  6. Effects of ovarian ablation or suppression in premenopausal breast cancer: A meta-analysis of randomized controlled trials.

    European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology · December 5, 2016 · Meta-analysis · cited 23 times

    PMID 28024943 · DOI 10.1016/j.ejso.2016.11.011 · Reviews and meta-analyses

  7. Degarelix for the treatment of advanced prostate cancer compared with GnRh-Agonists: a systematic review and meta-analysis.

    Medical journal of the Islamic Republic of Iran · January 9, 2016 · Meta-analysis · cited 16 times · open access

    PMID 27390687 · Reviews and meta-analyses

  8. Non-steroidal antiandrogen monotherapy compared with luteinising hormone-releasing hormone agonists or surgical castration monotherapy for advanced prostate cancer.

    The Cochrane database of systematic reviews · June 30, 2014 · Meta-analysis · cited 69 times · open access

    PMID 24979481 · DOI 10.1002/14651858.cd009266.pub2 · Reviews and meta-analyses

  9. Laparoscopic surgery for endometriosis.

    The Cochrane database of systematic reviews · April 3, 2014 · Meta-analysis · cited 347 times · open access

    PMID 24696265 · DOI 10.1002/14651858.cd011031.pub2 · Reviews and meta-analyses

  10. Non-surgical interventions for the management of chronic pelvic pain.

    The Cochrane database of systematic reviews · March 5, 2014 · Meta-analysis · cited 153 times · open access

    PMID 24595586 · DOI 10.1002/14651858.cd008797.pub2 · Reviews and meta-analyses

Most cited

By OpenAlex citation count. Citations measure attention, not quality or correctness.

  1. Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial.

    Lancet (London, England) · July 1, 2002 · Randomized controlled trial · cited 1,688 times

    PMID 12126818 · DOI 10.1016/s0140-6736(02)09408-4 · Human clinical research

  2. Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin.

    The New England journal of medicine · July 1, 1997 · Randomized controlled trial · cited 1,548 times · open access

    PMID 9233866 · DOI 10.1056/nejm199707313370502 · Human clinical research

  3. Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer.

    The New England journal of medicine · December 1, 1999 · Randomized controlled trial · cited 1,191 times

    PMID 10588962 · DOI 10.1056/nejm199912093412401 · Human clinical research

  4. Endocrine therapy plus zoledronic acid in premenopausal breast cancer.

    The New England journal of medicine · February 1, 2009 · Randomized controlled trial · cited 1,025 times · open access

    PMID 19213681 · DOI 10.1056/nejmoa0806285 · Human clinical research

  5. External irradiation with or without long-term androgen suppression for prostate cancer with high metastatic risk: 10-year results of an EORTC randomised study.

    The Lancet. Oncology · October 7, 2010 · Randomized controlled trial · cited 948 times

    PMID 20933466 · DOI 10.1016/s1470-2045(10)70223-0 · Human clinical research

Latest publications

  1. Comparison of cardiovascular events in patients with metastatic hormone sensitive prostate cancer treated with LHRH agonists to LHRH antagonists in the US: A retrospective cohort study.

    Urologic oncology · October 18, 2026 · Observational human study · cited 0 times

    PMID 42892580 · DOI 10.1016/j.urolonc.2026.09.012 · Human clinical research

  2. Extrauterine Adenomyoma of the Lung: A Rare Case Report.

    International journal of women's health · September 5, 2026 · Case report · cited 0 times · open access

    PMID 42719860 · DOI 10.2147/ijwh.s596873 · Human clinical research

  3. Fewer Injections and Lower Drug Costs With Long-Acting GnRH Depot Formulations: A Nationwide Analysis of 2.3 Million Patient-Years in Japan.

    Cancer reports (Hoboken, N.J.) · September 1, 2026 · Observational human study · cited 0 times · open access

    PMID 42728640 · DOI 10.1002/cnr2.70688 · Human clinical research

  4. Impact of leuprolide and goserelin on androgen suppression and adverse events in patients with prostate cancer.

    The Canadian journal of urology · August 21, 2026 · Randomized controlled trial · cited 0 times · open access

    PMID 42682049 · DOI 10.32604/cju.2026.069559 · Human clinical research

  5. Efficacy and safety of goserelin vs. leuprolide in premenopausal breast cancer patients receiving adjuvant endocrine therapy: A retrospective cohort study.

    Medwave · August 19, 2026 · Observational human study · cited 0 times · open access

    PMID 42617170 · DOI 10.5867/medwave.2026.07.3216 · Human clinical research

  6. Efficacy of goserelin combined with laparoscopic surgery for endometriosis and its effects on ovarian function and oxidative stress.

    American journal of translational research · August 15, 2026 · Observational human study · cited 0 times · open access

    PMID 42769464 · DOI 10.62347/dndw4937 · Human clinical research

  7. Darolutamide Alone and in Combination With Goserelin in Androgen Receptor-Positive Salivary Gland Carcinoma: Results From the Phase II DISCOVARY Trial.

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology · August 3, 2026 · Other clinical trial · cited 0 times · open access

    PMID 42546251 · DOI 10.1200/jco-25-03028 · Human clinical research

  8. Comparative effectiveness and integrated safety of goserelin sustained-release microspheres versus implants in prostate cancer: a patient-based real-world study and systematic review with meta-analysis.

    Frontiers in oncology · June 17, 2026 · Observational human study · cited 0 times · open access

    PMID 42388614 · DOI 10.3389/fonc.2026.1858453 · Human clinical research

  9. Thoracoabdominal endometriosis mimicking pulmonary tuberculosis in a TB-endemic setting: a case report.

    Journal of medical case reports · June 14, 2026 · Case report · cited 0 times · open access

    PMID 42289750 · DOI 10.1186/s13256-026-06150-4 · Human clinical research

  10. Pathological complete response to perioperative treatment with darolutamide plus ADT in locally advanced prostate cancer without PTEN or RB1 loss: a case report.

    Frontiers in pharmacology · June 3, 2026 · Case report · cited 0 times · open access

    PMID 42318353 · DOI 10.3389/fphar.2026.1829605 · Human clinical research

Browse all 1,957 publications in the dashboard

How this is counted

PubMed records matched by the names below, counted when the peptide is in the title, indexed by MeSH, or confirmed from the abstract. The exact query can be rerun on Europe PMC. Methodology

Search terms: Goserelin; Goserelina; Gosereline; Goserelinum; ICI-118630; Zoladex

((TITLE_ABS:"Goserelin" OR CHEM:"Goserelin") OR (TITLE_ABS:"Goserelina" OR CHEM:"Goserelina") OR (TITLE_ABS:"Gosereline" OR CHEM:"Gosereline") OR (TITLE_ABS:"Goserelinum" OR CHEM:"Goserelinum") OR (TITLE_ABS:"ICI-118630" OR CHEM:"ICI-118630" OR TITLE_ABS:"ICI118630" OR CHEM:"ICI118630") OR (TITLE_ABS:"Zoladex" OR CHEM:"Zoladex")) AND SRC:MED

Cite this page

Peptide Library. (2026, November 2). Goserelin research statistics (Version weekly-2026-11-01) [Statistic]. Peptide Library. https://peptidelibrary.app/research/peptides/goserelin